Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Under Armour Inc Class A (UA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Under Armour Inc Class ATrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Under Armour Inc Class A vs Vertex Pharmaceuticals Incorporated — how do they compare? Under Armour Inc Class A trades at $5.12 (market cap $2.26B), while Vertex Pharmaceuticals Incorporated trades at $528.16 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 59.4× Under Armour Inc Class A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.

UAVRTX
Market Cap
$2.26B$134.25B
Sector
Consumer CyclicalHealth
52-Week High
$7.88$529.65
52-Week Low
$3.96$376.62
Enterprise Value
$3.24B$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Under Armour Inc Class A

Under Armour (UA) trades at $5.20, down 8.37% amid weak quarterly results and lowered revenue guidance. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability (net margin -9.99%). Recent news highlights softer consumer demand in key markets, though the company maintains its profitability outlook.

The outlook remains challenging with significant execution risks and competitive pressures. While analyst sentiment is mixed (38.81% Buy, 49.25% Hold), the stock's deep value metrics (P/S 0.45) may attract contrarian investors if operational improvements materialize. Key risks include sustained revenue declines and negative cash flow trends.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.

Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.

Returns comparison

Trailing returns across standard periods

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX